START HERE — THE NURSING PRIORITY Always assess before administering any of these medications. Check the ordered parameters, heart rate/rhythm, blood pressure, symptoms, relevant ECG findings, and medication-specific laboratory requirements. Antiarrhythmics can themselves cause bradycardia, hypotension, conduction abnormalities, or new/prolonged arrhythmias. Use ordered hold parameters and clarify concerns rather than making assumptions.
1. Cardiac Terms You Must Know
Chronotropy: effect on heart rate. Positive chronotropy increases heart rate; negative chronotropy decreases it.
Dromotropy: effect on conduction speed, especially through the AV node. Negative dromotropy slows conduction.
Inotropy: effect on myocardial contractility. Negative inotropy decreases contractile force.
Automaticity: the heart’s ability to generate spontaneous electrical impulses.
Refractory period: the period during which cardiac tissue cannot be re-excited normally; increasing refractoriness can help interrupt reentry circuits.
Ejection Fraction (EF): The percent of blood ejected from the heart with each beat. As an example, if there is 100mL of blood in the left ventricle at the end of diastole, and 60mL of blood is ejected with the next heartbeat, the EF would be 60%. When discussing reduced ejection fraction, we are discussing an EF of < 35%.
ECG CONNECTION: Connect medication effects to the ECG: slowed AV-node conduction affects conduction/PR behavior; delayed ventricular repolarization can prolong QT/QTc. A prolonged QT increases concern for torsades de pointes.
2. Vaughan Williams Classification — The Framework
The Vaughan Williams system groups antiarrhythmics by predominant mechanism. It is useful for nursing-school exams, but several drugs have effects in more than one class.
Rapid IV administration, transient AV block, rhythm-specific use
3. Class I — Sodium Channel Blockers
IA: Quinidine, Procainamide
Moderate sodium-channel blockade with effects that can prolong repolarization and QT interval.
Less commonly used because of proarrhythmic risk and adverse-effect profiles.
Nursing focus: ECG monitoring when indicated, rhythm changes, QT/QTc monitoring, BP, and medication-specific toxicities.
IB: Lidocaine, Mexiletine
Milder sodium-channel blockade; class IB drugs shorten ventricular action-potential duration/QT in the appropriate electrophysiologic context.
Lidocaine is used primarily for ventricular arrhythmias in acute/monitored settings; mexiletine is an oral analog used for selected ventricular arrhythmias.
Nursing focus: ECG/rhythm, neurologic effects, BP, and medication-specific dosing/monitoring.
IC: Flecainide, Propafenone
Strong sodium-channel blockade with little direct effect on QT duration.
Used for selected atrial arrhythmias in patients without significant structural or ischemic heart disease.
Class IC drugs can be proarrhythmic in structural heart disease and after myocardial infarction; this is a major exam/clinical distinction.
HIGH-YIELD Do not memorize Class IC drugs as simply ‘strong sodium blockers.’ Remember the safety concept: flecainide and propafenone are generally avoided in significant structural heart disease/post-MI because of proarrhythmic risk.
4. Class II — Beta Blockers
Reduce sympathetic stimulation and produce negative chronotropic, dromotropic, and inotropic effects.
Commonly used for ventricular rate control in atrial fibrillation/flutter and selected supraventricular arrhythmias.
Major nursing concerns: bradycardia, hypotension, AV block, fatigue, and bronchospasm risk in susceptible patients.
BEFORE YOU GIVE IT Always assess heart rate, rhythm, and blood pressure before administering a beta-blocker used for rhythm/rate control. Follow the prescribed hold parameters. If the patient is close to the threshold, symptomatic, or clinically changing, reassess and clarify the order with the provider rather than relying on the number alone.
5. Class III — Potassium Channel Blockers
Class III drugs primarily delay repolarization, increasing the refractory period and often prolonging QT/QTc.
Many require continuous ECG monitoring because excessive QT prolongation can increase torsades risk.
Sotalol has both beta-blocking and class III effects.
Amiodarone has effects spanning several antiarrhythmic classes.
QT/QTc = KEY SAFETY CONCEPT When a medication prolongs QT/QTc, think ‘repolarization problem → torsades risk.’ Review ECG and relevant electrolytes, especially potassium and magnesium, and follow monitoring requirements.
6. Amiodarone — Know This One Well
Long-term therapy can cause pulmonary toxicity, including pulmonary fibrosis.
Hepatic metabolism is clinically important; liver function should be monitored and therapy reassessed with significant hepatic injury.
Can cause thyroid dysfunction, bradycardia/conduction abnormalities, and other systemic adverse effects. Baseline thyroid function should be obtained prior to initiation.
Drug interactions are numerous; medication reconciliation is particularly important.
Long-term therapy requires ongoing monitoring rather than treating amiodarone as a simple ‘heart rhythm pill.’
CLINICAL PEARL — LONG-TERM AMIODARONE Think beyond the rhythm: lungs, liver, thyroid, ECG, and drug interactions all matter. New respiratory symptoms, significant liver abnormalities, thyroid abnormalities, or clinically important bradycardia/conduction changes should prompt evaluation.
7. Class IV — Nondihydropyridine Calcium Channel Blockers
Diltiazem and verapamil slow AV-node conduction and reduce heart rate and contractility.
Commonly used for ventricular rate control in atrial fibrillation/flutter and selected stable SVTs.
Important adverse effects: bradycardia, hypotension, AV block, and peripheral edema.
Use caution/avoidance in significant systolic dysfunction depending on the clinical situation because of negative inotropic effects.
HIGH-YIELD Diltiazem/verapamil are AV-node slowing drugs. If the patient is already bradycardic, hypotensive, or has significant systolic dysfunction, the medication deserves particular scrutiny before administration.
8. Adenosine — A Special Case
Used to terminate AV-node–dependent SVTs such as AVNRT and orthodromic AVRT and can help reveal underlying atrial activity diagnostically.
It has an extremely short half-life and is administered as a rapid IV bolus followed immediately by a flush according to protocol.
It can produce a brief period of AV-node block, with transient profound slowing/asystole on the monitor. Note the phrasing “Profound slowing,” it is commonly stated this medication “Stops the heart.” This is a common misconception fueled by how long a transient pause in cardiac conduction can feel. In rare cases, predominantly in the elderly or other frail patients, you may experience prolonged pausing or true asystole.
Patients may experience flushing, chest discomfort, or a frightening sense of impending doom because of its transient effects.
It is not effective for atrial fibrillation or atrial flutter themselves because those rhythms do not depend on the AV node for their maintenance.
Asthma/bronchospasm risk and accessory-pathway rhythms require special attention; follow current clinical guidance.
NURSING PRIORITY Adenosine should be given only with appropriate monitoring and resuscitation capability available. Explain that a brief, uncomfortable sensation can occur so the patient is not surprised, while continuing to monitor rhythm and clinical status.
9. Rhythm First: The Medication Depends on the Patient
Is the patient hemodynamically stable? Hypotension, altered mental status, shock, or significant hypoxia changes the urgency and management pathway.
What rhythm is present? Identify whether it is narrow/wide complex and regular/irregular when possible.
What is the ventricular rate?
Is the medication intended to control ventricular rate, convert the rhythm, or maintain sinus rhythm?
Does the patient have structural heart disease, reduced EF, ischemic heart disease, conduction disease, asthma, renal/hepatic impairment, or electrolyte abnormalities affecting medication selection?
What does the current ECG and QT/QTc show?
CLINICAL MANAGEMENT KEY A rhythm problem plus hemodynamic instability is not primarily a ‘which medication?’ question. Stabilization and the appropriate emergency rhythm-management pathway take priority. For stable patients, medication selection depends on the specific rhythm and patient characteristics.
10. Safe Administration & Monitoring
Always assess before administering any of these medications: current heart rate/rhythm, blood pressure, symptoms, ordered hold parameters, and relevant ECG/laboratory information.
Review the medication’s specific monitoring requirements. Some agents require continuous telemetry or ECG monitoring.
Check potassium and magnesium when clinically relevant, especially with medications that can prolong QT/QTc.
Assess renal function for drugs substantially renally cleared and requiring renal dosing/monitoring, such as dofetilide.
Assess hepatic function when clinically relevant, particularly with medications substantially metabolized by the liver such as amiodarone.
Do not withhold a chronic antiarrhythmic solely because a value is close to a hold parameter. Reassess the patient, review the exact order, and clarify concerns with the appropriate provider.
Do not assume that a medication is safe simply because the patient has tolerated it previously. New changes in rhythm, BP, renal function, electrolytes, or symptoms can change risk.
11. The Hold-Parameter Trap
Example: If the order says to hold for HR <60 and the HR is 62, the medication is not automatically ‘safe’ simply because the number is above 60.
Look at the whole picture: Is the patient symptomatic? Is the rhythm new? Is the BP low? Is there a conduction abnormality? Is the patient receiving other rate-slowing medications?
If there is concern about administration, clarify with the provider and document according to policy.
Do not invent a hold parameter that is not ordered or supported by policy. Follow the actual prescription and institutional guidance.
KEY POINT The medication’s purpose matters. Chronic antiarrhythmics may be preventing recurrence of a dangerous rhythm. A missed dose can matter. The correct response to uncertainty is assessment + order review + clinical clarification, not automatic withholding or automatic administration.
OpenStax. Pharmacology for Nurses, Chapter 17: Dysrhythmias. Rice University. https://openstax.org/books/pharmacology/pages/17-1-introduction-to-dysrhythmias
OpenStax. Pharmacology for Nurses, Chapter 17 Summary. Rice University. https://openstax.org/books/pharmacology/pages/17-chapter-summary
Educational note: This guide is for nursing education and does not replace current medication references, institutional protocols, provider orders, ACLS guidance, or pharmacist/clinician judgment. Antiarrhythmics are medication-specific and may require specialized monitoring, dosing, or initiation protocols.
Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
